Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
US7582291B2 · kind B2 · utility
17Cited by
20References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 24, 2006 |
| Grant date | Sep 1, 2009 |
| Priority date | — |
| Expiry date | May 24, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y302/01017
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to bacteriophage lysins useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, bacteriophage lysins were isolated and shown to effectively kill various bacteria, including both E. faecalis and E. faecium (including vancomycin resistant strains), as well as other human pathogens.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.